Shao-Lee Lin, Acelyrin CEO (Vanja Sabic/Nasdaq, Inc)
May 5, 2023 11:34 AM EDT
Financing
Startups

Q&A: Ace­lyrin CEO Shao-Lee Lin de­tails biotech's $540M IPO, find­ing 'di­a­monds in the rough'

Kyle LaHucik

Senior Reporter

Ace­lyrin start­ed trad­ing on the Nas­daq Fri­day morn­ing in one of the largest biotech ini­tial pub­lic of­fer­ings in re­cent mem­o­ry, with $540 mil­lion in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Sanofi to pay $125M up­front for two im­munol­o­gy drugs from lit­tle-known biotech

US drugs re­ly heav­i­ly on in­gre­di­ents made over­seas, new re­port shows

Ex­clu­sive: VelaV­i­go inks an­oth­er US biotech deal as Chi­na drug de­vel­op­ment scene booms

Sarep­ta los­es CMO to RNA edit­ing up­start; An­oth­er wave of per­son­nel moves at Dyne

Biotech seed rounds sink to low­est lev­el in years as in­dus­try slump drags on

sponsored

New York-based part­ner­ship sets the stan­dard for ex­pand­ing clin­i­cal tri­al ac­cess for un­der­served and di­verse ...

A service from the Financial Times